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This study demonstrated that the λ- and ι-carrageenans, sulfated polysaccharides containing linear chains of galactopyranosyl residues, are
potent inhibitors of dengue virus type 2 (DENV-2) and 3 (DENV-3) multiplication in Vero and HepG2 cells, with values of effective concentration
50% from 0.14 to 4.1 μg/ml. This activity was assayed by plaque reduction, virus yield inhibition and antigen expression tests, and was
independent of the input multiplicity of infection in the range 0.001–1. The inhibitory action of the λ-carrageenan, an heparan sulfate (HS)-
imitative compound, was exerted by a dual interference with virus adsorption and internalization of nucleocapsid into the cytoplasm. Although
virus particles may enter the cell when compound was added after DENV-2 adsorption, as shown by intracellular uptake of radiolabeled DENV-2
particles and quantitative RT-PCR, infectious center and virion uncoating assays have shown that carrageenan-treated virions cannot be released
from the endosomes. Viral protein synthesis, the first step of macromolecular synthesis after DENV entry to the host cell, was not affected by the
carrageenan. Furthermore, no inhibition of virus multiplication was detected when the entry process was bypassed through DENV-2 RNA
transfection into the cell. The dual sites of action of an HS-like molecule suggest that, at least in monkey kidney and human hepatic cells, the HS
residues in the cell membrane appear to act as mediators for DENV-2 entry, an interesting alternative target for flavivirus therapy.
© 2007 Elsevier Inc. All rights reserved.Keywords: Dengue virus; Flavivirus; Carrageenan; Virus entry; Adsorption; Internalization; Uncoating; Heparan sulfateIntroduction
Dengue virus (DENV), a member of family Flaviviridae
genus Flavivirus, is the agent of the most prevalent arthropod-
borne viral disease in humans. Currently, it is estimated that the
virus is endemic in more than 100 countries, producing about 50
million infections each year (Gubler, 2002). DENV exists as
four antigenically distinct serotypes, DENV type 1 (DENV-1) to
DENV-4, which cocirculate in tropical and subtropical regions
transmitted to human by two species of mosquitoes, Aedes
aegypti and Aedes albopictus. Although most primary infec-
tions are asymptomatic, the four serotypes can cause dengue
fever (DF), a mild febrile illness that in a minority of cases
progresses to the severe and life-threatening dengue hemor-
rhagic fever and dengue shock syndrome (DHF/DSS). Primary
infection provides immunity against the infecting serotype, but
the secondary infection with another serotype appears to⁎ Corresponding author. Fax: +54 11 4576 3342.
E-mail address: edamonte@qb.fcen.uba.ar (E.B. Damonte).
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doi:10.1016/j.virol.2007.01.043enhance the risk of developing DHF/DSS through an
immunopathological process named antibody-dependent
enhancement (ADE) (Halstead, 1979; Kliks et al., 1989). Host
genetic and immunological factors as well as genetic variation
in virulence among DENV strains also appear to contribute to
DHF and DSS pathogenesis (Holmes and Burch, 2000;
Leitmeyer et al., 1999; Rico-Hesse et al., 1997; Rothman and
Ennis, 1999). Despite the increasing incidence and emergence
of dengue infections around the world, there are no antiviral
agents or vaccines available against DENV, and little is known
about the entire replication cycle of DENV in mosquito or
vertebrate cells.
The virion contains a single-stranded, positive-sense RNA
molecule of approximately 11 kb in length, inserted in an
icosahedral nucleocapsid and surrounded by a lipid envelope
covered with peplomers. The genome is translated into three
structural proteins (the capsid protein C, a small nonglycosy-
lated membrane protein M and the envelope glycoprotein E)
and seven non-structural proteins (NS1, NS2A, NS2B, NS3,
NS4A, NS4B and NS5).
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the antiviral efficacy of diverse natural and synthetic products
against DENV, including sulfated polysaccharides obtained
from South American seaweeds (de S.F-Tischer et al., 2006;
Pujol et al., 2002; Rodríguez et al., 2005; Talarico et al., 2005),
essential oils extracted from aromatic plants (Duschatzky et al.,
2005; García et al., 2003) and carbonucleoside analogues
(Martins Alho et al., 2005). Among this variety of tested
compounds, sulfated polysaccharides were as far the more
successful inhibitors of DENV in vitro infection, apparently
based on the structural similarities with the heparan sulfate (HS)
residues of cell membrane proteoglycans. HS is constituted by
polyanionic carbohydrate chains and is present abundantly on
the surface of most animal cells serving as a receptor for various
ligands (Bernfield et al., 1999; Rostand and Esko, 1997;
Spillmann, 2001). An involvement of HS during initial stages of
DENV replicative cycle has been suggested by several reports,
but the specific functional role of HS during infection is still
unresolved. Controversial results have suggested that HS could
act directly as a receptor for attachment and entry (Chen et al.,
1997; Germi et al., 2002; Hilgard and Stockert, 2000; Hung et
al., 1999), HS may be required only to recruit virions on the cell
surface to facilitate the interaction with a high-affinity co-
receptor of protein nature (Martínez-Barragán and del Angel,
2001; Thepparit and Smith, 2004), or even HS may not be
necessary for DENV infection (Bielefeldt-Ohmann et al., 2001).
Given the wide host range of DENV, these discrepancies may be
ascribed to differences in the interactions leading to virus entry,Table 1
Chemical structure of carrageenans and spectrum of antiviral activity against DENV
Compound CC50
(μg/ml) a
EC50 (μ
DENV-
>1000 40.7±4
>1000 >50
>1000 >50
a Cytotoxic concentration 50%, concentration required to reduce Vero cell viabilit
b Effective concentration 50%, concentration required to reduce DENV plaque num
deviation.as receptor usage and internalization, depending on DENV
serotype, passage history of the virus and host cell type.
Here, we report on the analysis of the effect of HS-imitative
compounds on DENV infection of monkey kidney and human
hepatic cells. Based on our previous studies with algal-derived
polysaccharides against herpesvirus (Damonte et al., 2004a) and
DENV infections, three chemical classes of carrageenans were
chosen as potential inhibitors. Carrageenans are sulfated galactans
consisting of linear chains of alternating 1–3 β-D-galactopyr-
anosyl residues (A units) and 1–4 α-D-galactopyranosyl or D-3,6-
anhydrogalactosyl residues (B units), which comprise a broad
range of structural classes (Stortz and Cerezo, 2000). The steps in
the DENV-2 life cycle inhibited by carrageenans were localized
providing evidence that HS functions for virus attachment and
entry in both types of vertebrate cells and showing an effective
alternative for antiviral strategies.
Results
Inhibition of DENV infection by carrageenans
To evaluate the antiviral activity of carrageenans on DENV
infection, ι-, λ- and κ-carrageenans were assayed for their
ability to inhibit DENV plaque formation in Vero cells. As
previous studies have reported differential antiviral suscept-
ibility among DENV serotypes (Lin et al., 2002; Talarico et al.,
2005), the four serotypes were initially evaluated in a plaque
reduction assay. As can be seen in Table 1, the three types ofserotypes
g/ml) b
1 DENV-2 DENV-3 DENV-4
.9 0.4±0.1 4.1±0.1 8.2±0.1
0.15±0.04 2.0±0.3 4.2±1.1
1.8±0.3 6.3±0.1 >50
y by 50%.
ber in Vero cells by 50%. Each value is the mean of duplicate assays±standard
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but with a variable level of effectiveness according to the
compound and the virus serotype. DENV-2 and DENV-3 were
the most susceptible viruses to these polysaccharides with
values of effective concentration 50% (EC50) lower than 10 μg/
ml for the three compounds. The λ- and ι-carrageenan were, in
that order, the most active agents, and particularly DENV-2
exhibited the highest inhibition with EC50 values lower than
1 μg/ml for these two types of carrageenans. By contrast, the
susceptibility of the other two serotypes, DENV-4 and DENV-1,
was very irregular. Again, the λ- and ι-carrageenan exhibited a
higher degree of inhibitory action against DENV-4 in com-
parison to the κ-carrageenan, whereas DENV-1 was as far the
less sensitive serotype. Vero cell viability was not affected by
the three compounds as determined by the MTT assay at
concentrations up to 1000 μg/ml (Table 1). Thus, the inhibition
of ι- and λ-carrageenan against DENV-2 and DENV-3 can be
considered highly specific since the selectivity indices, i.e. the
relationship between cytotoxic concentration 50% (CC50) and
EC50, are in the range 2500–6666, for DENV-2, and 244–500,
for DENV-3, respectively.
To confirm the potent antiviral action of the most effective
compounds, λ- and ι-carrageenans, against DENV-2 and
DENV-3, the inhibitory activity was assessed in an assay
performed at a multiplicity of infection higher than that
allowable in a plaque reduction test. To this end, a virus yield
inhibition assay was performed by inoculation of cells at an m.
o.i. of 0.1 and titration of virus production after 48 h of infection
in the presence of serial two-fold drug concentrations. Clinical
studies have shown the presence of DENV antigen and nucleic
acid in the liver of DF patients (Couvelard et al., 1999; Rosen et
al., 1999), indicating that hepatocytes may be a target capable of
supporting in vivo DENV replication. Consequently, we
decided to perform in parallel a virus yield reduction assay in
the human hepatoma-derived cell line HepG2, representative of
the host tissue in natural infection. Results are shown in Table 2.
For Vero cells, the values of EC50 against DENV-2 and DENV-3
are of similar order as those obtained for the plaque reduction
assay (Table 1). With respect to the human HepG2 cells, the
reduction in DENV-2 and DENV-3 production in the presence
of the carrageenans was also dose-dependent as in Vero cells
and with high effectiveness since the EC50 values wereTable 2
DENV-2 and DENV-3 yield inhibition in Vero and HepG2 cells
Compound EC50 (μg/ml)
a
Vero HepG2
DENV-2
ι-carrageenan 0.4±0.1 0.14±0.01
λ-carrageenan 0.22±0.02 0.17±0.01
DENV-3
ι-carrageenan 1.1±0.1 0.63±0.01
λ-carrageenan 0.6±0.1 0.63±0.01
a Effective concentration 50%: concentration required to inhibit virus yield
at 48 h post-infection by 50%. Each value represents the mean of duplicate
assays±standard deviation.consistently lower than 1 μg/ml. As reported for Vero cells,
there was no difference in cell viability between untreated
HepG2 cells and cells treated with as much as 1000 μg/ml of
carrageenans (data not shown).
Results presented in Tables 1 and 2 suggest that the antiviral
activity of carrageenans against DENV-2 and DENV-3 is
independent of the method employed for evaluation (plaque or
yield reduction) and, even more important, of the input
multiplicity of infection (0.001 in plaque assay vs. 0.1 in
yield reduction test). To assess the independence of carrageenan
effectiveness with virus inoculum, dose response curves for
DENV-2 and DENV-3 with both carrageenans were performed
by virus yield inhibition assay at a range of m.o.i. from 0.01 to
1. As seen in Fig. 1, the inhibitory effects of λ- and ι-
carrageenan were not dependent of the inoculating dose of
DENV-2 and DENV-3, with only slight variations in the
percentage of inhibition at very low compound concentrations.
In fact, the values of EC50 for λ-carrageenan calculated from
data in Figs. 1A and C were in the range 0.15–0.39 μg/ml
against DENV-2 and 1.40–2.28 μg/ml against DENV-3,
respectively. Thus, with a 100-fold higher virus inoculum, the
EC50 value was about or less than 2-fold higher than the value
obtained when evaluated at the lower inoculum. Similar
variation in EC50 values was observed for ι-carrageenan.
The effects of carrageenans on DENV infection were also
monitored using an indirect immunofluorescence assay to
determine viral antigen expression. Vero and HepG2 cells were
exposed to carrageenans simultaneously with virus infection,
and at 48 h p.i. viral antigen expression was detected by
immunostaining with anti-DENV antibodies. The results of a
representative experiment are shown in Fig. 2. In DENV-2
infected Vero and HepG2 cells, a regular dotted distribution of
viral proteins in cell cytoplasm was revealed (Figs. 2A and E).
The number of DENV-2 antigen-expressing cells was drasti-
cally reduced by λ-carrageenan, with the detection of very few
sporadic positive cells (Figs. 2B and F). In fact, the percentage
of infected cells per microscope field showing DENV-2
immunofluorescence in the presence of λ-carrageenan with
respect to infected untreated controls was lower than 1%. A
similar pattern of reduction in DENV-2 antigen expression was
observed after treatment with ι-carrageenan (Figs. 2C and G).
Influence of time of treatment with carrageenans on DENV
infectivity
The DENV-2 serotype and the λ-carrageenan were chosen as
model system to further study the mode of action of carrageenans
against DENV infection. Mechanistic studies were performed at a
carrageenan concentration of 20 μg/ml in order to assess a high
inhibitory effect in all the assays designed to elucidate the mode
of action of the compounds. As an initial approach, a time course
study was done to analyze the influence of the time of addition of
the compound during the virus multiplication cycle. The λ-
carrageenan was added to Vero and HepG2 cells simultaneously
with virus or at hourly intervals after adsorption of virus to the
cells. A high inhibitory effect was observed when the compound
was added to cells together with the virus (time 0) or immediately
Fig. 1. Inhibition of DENV-2 and DENV-3 production by carrageenans at different multiplicities of infection. Vero cells were infected at a range of m.o.i. from 0.01 to 1
with DENV-2 (A, B) or DENV-3 (C, D) in the absence or presence of increasing concentrations of λ-carrageenan (A, C) or ι-carrageenan (B, D). Extracellular virus
yields were determined at 48 h p.i. by a plaque assay in Vero cells. Results are expressed as percent of inhibition in compound-treated cultures compared to untreated
ones. Each value is the mean of duplicate assays±standard deviation.
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experimental conditions, virus yields were reduced more than
95% in both Vero and HepG2 cells (Fig. 3A). By contrast, no
significant reduction in virus multiplication was observed when
the carrageenan was incorporated after 2 h of infection. TheseFig. 2. Effect of carrageenans on DENV-2 antigen expression. Vero (A–D) and Hep
absence (A and E) or presence of 20 μg/ml of λ-carrageenan (B and F) or ι-carragee
anti-DENV mouse antibodies. Magnification: 400×.results locate the antiviral target of these polysaccharides in a
very early stage of the virus cycle, during the first hour of
infection and previous to the second hour of infection.
Based on the results obtained, we next investigated the stage
in the viral life cycle at which the carrageenan blocked infectionG2 (E–H) cells were mock infected (D and H) or infected with DENV-2 in the
nan (C and G). At 48 h p.i., immunofluorescence staining was carried out using
Fig. 3. Influence of time of treatment with λ-carrageenan on anti-DENV-2
activity. (A) Vero and HepG2 cells were infected with DENV-2 and compound
(20 μg/ml) was added simultaneously with virus (time 0) or at the indicated
times after infection. At 10 h p.i. medium was discarded and an infectious center
(IC) assay was performed in Vero cells. (B) Vero and HepG2 cells were infected
with DENV-2 under three different treatment conditions. Virus adsorption: cells
were infected in MM containing 20 μg/ml of compound and, after 1 h adsorption
at 4 °C, were overlaid with compound-free MM. Virus internalization: DENV-2
was adsorbed to Vero cells at 4 °C, then MM containing 20 μg/ml of compound
was added and incubation continued at 37 °C for 2 h. Then, cells were treated
with citrate buffer and covered with MM. Virus adsorption and internalization:
cells were infected and maintained in the presence of 20 μg/ml of compound
during 1 h adsorption at 4 °C and 2 h internalization at 37 °C and then processed
as above. For the three treatments, virus yields were determined at 48 h p.i. by a
plaque assay in Vero cells. Results are expressed as percent of inhibition in
compound-treated cultures compared to untreated ones. Each value is the mean
of duplicate assays±standard deviation.
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during the first hour of infection. First, the effect of carrageenan
on the events leading to viral entry in the host cell was studied by
evaluation of the inhibitory action of the compound on virus yield
after 48 h of infection when present exclusively during virus
adsorption or/and virus internalization. As shown in Fig. 3B, a
significant antiviral effect (inhibition in the range 86.6–96.2%)
occurred when the carrageenan was present only during virus
adsorption at 4 °C. If adsorption took place in a drug-freemedium, and the compound was added at culture supernatants
when the temperature was raised at 37 °C and maintained only
during 2 h of incubation, the virus yield determined at 48 h p.i.
was also significantly affected in comparison with untreated
cultures (96.1–96.6% inhibition). As expected, the presence of
the carrageenan during both adsorption at 4 °C and internaliza-
tion at 37 °C exerted the maximum level of reduction in virus
yield with 99.1–99.9% inhibition.
Inhibition of DENV-2 adsorption and internalization
To confirm the effect of λ-carrageenan on DENV-2 adsorp-
tion and penetration, different experimental approaches were
intended. For both stages of the multiplication cycle, the amount
of bound or internalized virus in the presence of compound was
measured by infectivity assays, quantification of cell-associated
viral RNA molecules and radiolabeled virus particles.
The inhibition of virus adsorption by the carrageenan was
demonstrated by the three assays abovementioned. After DENV-
2 adsorption at 4 °C in the presence of 20 μg/ml of compound,
the amount of Vero cell-bound infectivity was inhibited about
90% (Fig. 4A). When the amount of cell-bound viral RNAwas
quantified by real-time RT-PCR in other set of cultures under the
same treatment conditions, a similar reduction in the number of
RNA molecules attached to the cells was observed (Fig. 4B).
Finally, the carrageenan also inhibited the binding of radi-
olabeled DENV-2 particles to Vero cells (Fig. 4C).
Next, the effect of carrageenan on DENV-2 penetration was
analyzed. Vero cells were allowed to adsorb virus in the absence
of compound, and then infected cultures were incubated at 37 °C
for 1 h in the presence of carrageenan. Thereafter, in a set of
cultures the amount of internalized virus was quantified by an
infectious center assay, whereas another set of cultures was
processed to determine the amount of viral RNA inside the cells.
As seen in Fig. 4D the number of infectious centers was reduced
about 2 log (99% inhibition) in cells incubated with the
carrageenan during 1 h after DENV-2 adsorption. By contrast,
under the same treatment conditions, the number of internalized
DENV-2 RNA molecules per culture was similar in compound-
treated and untreated cultures (Fig. 4E), suggesting that when the
carrageenan was added immediately after adsorption virus
particles entered the cell but they could not complete the
infectious process. To assess this possibility, a suspension of
purified radiolabeled DENV-2 particles was adsorbed to Vero
cells at 4 °C, then cultures were shifted to 37 °C in the presence of
carrageenan, and after 1 h of incubation, the amount of
radioactivity inside the cells was determined. The amount of
radiolabeled internalized virus was not affected by the carragee-
nan (Fig. 4F).
Although not clearly elucidated for all the family members,
flaviviruses are believed to enter cells by receptor-mediated
endocytosis (Lindenbach and Rice, 2001). Thus, the acid
environment of the endosome should induce conformational
changes in the E protein to allow the transport of nucleocapsid
to the cytoplasm. The controversial results shown in Figs. 4D–F
could be explained if carrageenan-treated DENV virions can
enter the cells but are not able to be uncoated and released from
Fig. 4. Effect of λ-carrageenan on virus adsorption and internalization. (A) DENV-2 was adsorbed to Vero cells at 4 °C for 1 h in MM containing or not 20 μg/ml of λ-
carrageenan. Then, cell-bound infectious virus was determined by plaque assay. (B) Vero cells were infected and treated as in A, then total RNAwas extracted and the
amount of adsorbed DENV-2 RNA molecules was determined by quantitative real-time RT-PCR. (C) Cells were incubated with 35S-labeled DENV-2 at 4 °C for 1 h in
the absence or presence of 20 μg/ml of λ-carrageenan, and then cell-bound radioactivity was determined. (D) DENV-2 was adsorbed to Vero cells at 4 °C for 1 h. After
incubation at 37 °C for 1 h in MM containing 20 μg/ml of λ-carrageenan, cell monolayers were treated with proteinase K and the cell pellet was plated onto Vero cells
to determine internalized virus by an infectious center (IC) assay. (E) Vero cells were infected and processed as in D, total RNAwas extracted and real-time RT-PCR
was performed to determine the amount of internalized viral RNAmolecules. (F) Cells were incubated with 35S-labeled DENV-2 at 4 °C for 1 h, then at 37 °C for 1 h in
MMwith carrageenan, processed as in D, and cell-internalized radioactivity was then measured. (G) DENV-2 was adsorbed to Vero cells at 4 °C for 1 h, and then cells
were incubated at 37 °C in MM containing or not carrageenan or concanamycin. At different times post-adsorption, non-internalized virus was removed, cells were
disrupted by freeze–thawing and intracellular infectivity was determined. VC: virus control, compound-untreated infected cells; λ-carrageenan: compound-treated
infected cells. Each value represents the mean of duplicate assays±standard deviation.
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Vero cells at 4 °C, and then infected cultures were further
incubated at 37 °C in the presence of carrageenan. At different
times post-adsorption, non-internalized virus was removed with
proteinase K and cell-associated infectivity was determined.
Virus uncoating and the consequent nucleocapsid delivery to the
cytoplasm seem to be the post-adsorption step affected bycarrageenan since no significant decrease in cell-associated
DENV infectivity was detected in treated cells whereas a
consistent reduction occurred in untreated infected cells (Fig.
4G). The accumulation of intracellular infectivity in carrageenan-
treated cells resembles that observed in concanamycin-treated
cultures (Fig. 4G). This compound was simultaneously assayed
as a positive control because it has been reported for other
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but prevents membrane fusion between virus envelope and the
endosomal membrane leading to nucleocapsid release into the
cytoplasm (Guinea and Carrasco, 1994; Irurzun et al., 1997).
Lack of inhibitory effect of carrageenan after DENV entry
After viral entry to the host cell, the first step of
macromolecular biosynthesis in DENV replication cycle is the
synthesis of viral proteins from the RNA positive strand
genome. To investigate whether carrageenan affects viral RNA
translation, Vero cells were pulsed with [35S]-cysteine-methio-
nine in the presence of the compound, during an early period in
the infection process after internalization is completed (12–Fig. 5. Lack of inhibitory effect of carrageenan after DENVentry. (A) Synthesis of vira
incubated with MM in the presence or absence of 20 μg/ml of λ-carrageenan. At 12 h
polypeptides were immunoprecipitated from cell lysates with rabbit anti-DENV-2 ser
infected cells; 3, λ-carrageenan-treated infected cells. Molecular mass markers are i
polypeptides. (B and C) Transfection of Vero cells with DENV-2 RNA. Vero cells gro
were incubated inMM containing or not 20 μg/ml of λ-carrageenan during 18 h. There
post-transfection, cells were stained with anti-DENV-2 mouse antibody plus FITC-go
untreated transfected cells; b: λ-carrageenan-treated transfected cells; c: mock transfe16 h) but compatible with an adequate detection of the main
viral polypeptides after immunoprecipitation. As seen in Fig.
5A, under these conditions, viral bands corresponding to the E
and prM polypeptides were clearly revealed in control untreated
infected cells (lane 2) as well as in carrageenan-treated cells
(lane 3). Altogether, these results indicate that the inhibitory
action of the carrageenan located in the first hour after infection
is specifically targeted to the stages of adsorption and
nucleocapsid internalization, previous to the macromolecular
biosynthetic events.
To assess that the carrageenan target is exclusively at the
DENVentry to the host cell and there is no effect in any further
stage, the inhibitory action of λ-carrageenan in cells transfected
with viral RNAwas also evaluated. To this end, DENV-2 RNAl proteins. Vero cells were infectedwith DENV-2, and after 1 h at 37 °C, cells were
p.i., cells were labeled with 100 μCi/ml of EXPRE35S-35S for 4 h and then viral
um and analyzed by electrophoresis. Lanes: 1, mock infected cells; 2, untreated
ndicated on the left; arrows on the right indicate the positions of the main viral
wn in coverslips were transfected with DENV-2 RNA, and 2 h later monolayers
after, cells were washed and further incubated inMMwithout compound. At 96 h
at anti-mouse IgG (B) and supernatants were harvested for PFU titration (C). a:
cted cells. VC: virus control, compound-untreated transfected cells.
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cells grown in coverslips with Lipofectamine as vehicle. After
96 h of transfection, the effect of λ-carrageenan on viral protein
expression and infectious particle production was determined.
The results show no inhibition of DENV multiplication in
RNA-transfected cells. A similar level of antigen-positive cells,
visualized as single cells or focuses containing 2–20 cells, was
detected by indirect immunofluorescence in λ-carrageenan-
treated or untreated cells. Fig. 5B shows large focuses repre-
sentative of those observed in microscope fields of untreated
and treated transfected cultures. Concomitantly, no reduction in
the amount of infectious particles released to cell supernatants
was detected by quantitative titration of PFU in λ-carrageenan-
treated cultures (Fig. 5C), indicating that when DENV-2 RNA
entered Vero cells through transfection bypassing the entry
process of virus particles the compound was not able to block
the formation of infectious virions.
Comparison of virucidal and antiviral activities
Finally, the possibility of an inactivating effect of carragee-
nans against cell-free DENV virions was also studied. In
particular, λ-carrageenans of natural origin were reported as
inactivating agents against herpes simplex virus (HSV) whereas
other structural types of carrageenans and sulfated polysacchar-
ides in general usually lack these inactivating properties and
only act blocking the binding of virions to the cell membrane
(Carlucci et al., 1999; Damonte et al., 2004a; McClure et al.,
1991). Thus, we decided to evaluate the virucidal activity of λ-
carrageenan by incubation of a DENV-2 suspension with the
compound at 37 °C during 45 min. Then, remaining infectivity
in the mixture was determined by plaque formation in Vero cells
and previous dilution of the sample to assure that, when the
compound virus suspensions are incubated on the cell mono-
layers, the compound concentration is below the antiviral EC50
value. For comparative purposes, the antiviral plaque reduction
assay was simultaneously performed with the same compound
concentrations. As seen in Fig. 6, the λ-carrageenan was able toFig. 6. Comparison of virucidal and antiviral activities. Virucidal: DENV-2
suspensions were incubated with 5 or 50 μg/ml of λ-carrageenan at 37 °C during
45 min and then the remaining infectivity was determined. Antiviral: plaque
reduction assay in Vero cells. Results are expressed as percent of inhibition in
carrageenan-treated samples compared to untreated ones. Each value is the mean
of duplicate assays±standard deviation.produce a very weak virucidal effect at very high concentrations
in comparison with its antiviral effectiveness. Only at a
concentration of 50 μg/ml a significant but low level of virus
inactivation, with 55.7% inhibition in remaining infectivity, was
detected. Thus, the ratio between VC50 (virucidal concentration
50%, concentration required to inactivate 50% of virions) and
antiviral EC50 was 211, indicating that the blockade observed in
the multiplication of DENV-2 in Vero and HepG2 cells can be
totally ascribed to an interference with the viral entry process.
Discussion
Studies reported here have proved that λ- and ι-carrageenans,
sulfated polysaccharides containing linear chains of galac-
topyranosyl residues, are potent inhibitors of DENV-2 and
DENV-3 multiplication in cells of monkey and human origin,
with values of selectivity indices in the range >244–>7143.
This activity was initially tested by plaque reduction assays,
necessarily performed at a low m.o.i., but then confirmed by
inhibition of virus yield and antigen expression assays, accom-
plished at high m.o.i., indicating that the ability of carrageenans
to interfere with DENV multiplication was independent of the
testing method and the input virus dose. In addition, when viral
antigen expression was measured by immunofluorescence
staining, the spreading ability of DENV-2 was also shown to
be greatly suppressed in the presence of the carrageenans, with a
drastic reduction in the number of infected cells as well as an
inhibition in the formation of giant fluorescent focus.
The lack of dependence of the antiviral potency of
carrageenans with the infecting virus inoculum was even
more evident when virus yield reduction assays were performed
simultaneously at a wide range of multiplicities (Fig. 1). This
important property is not unusual for antiviral agents, including
other types of DENV inhibitors (Whitby et al., 2005), but
represents a clear advantage for those compounds able to block
infection even in the presence of high initial virus doses. These
results provide support for the potential therapeutic use of these
carrageenans, suggesting that they might suppress the multi-
plication of sufficiently high concentrations of DENV-2 and
DENV-3 and, thus, prevent de novo infection of cells and virus
spreading.
Carrageenans of natural and commercial origin have been
evaluated as inhibitors of other enveloped viruses, including
HSV, cytomegalovirus and human immunodeficiency virus
(Baba et al., 1988; Bourne et al., 1999; Cáceres et al., 2000;
Carlucci et al., 1999; González et al., 1987; Hamasuna et al.,
1993; Talarico et al., 2004; Yamada et al., 2000). It was reported
that carrageenans act against these viruses by prevention of the
binding of virus to the HS residues in cellular proteoglycans and
consequently are responsible for blocking virus adsorption. In
the present study, different experimental approaches have
shown that the target for carrageenan in DENV-2 seems to be
extended not only to adsorption, as mentioned for other viruses,
but also to a post-adsorption event blocking the viral
nucleocapsid internalization into the cytoplasm. The first
inhibitory action in the prevention of virus adsorption when
DENV was adsorbed to the host cell in the presence of
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adsorbed virus, quantification of attached viral RNA molecules
and measure of radiolabeled virus particles (90% inhibition).
When the compound was added to infected cells after virus
adsorption, more than 95% inhibition of virus yield was
observed at 48 h p.i. Since no inhibition of virus multiplication
by carrageenan was detected when DENV-2 RNA was
introduced into the cell by transfection, the process affected
by carrageenan when added after adsorption must be an event
related to virus entry such as virus penetration or uncoating.
At present, the mechanism of DENV entry to the cell is a
controversial subject. Electron microscopic studies have shown
that DENV-2 penetrated directly into the cytoplasm of C6/36
and BHK cells by fusion of the virion envelope with the plasma
membrane at physiologic pH (Hase et al., 1989; Lim and Ng,
1999), but it is now generally accepted that for productive
flavivirus infection viral uptake occurs through receptor-
mediated endocytosis (Lindenbach and Rice, 2001). After
binding to the cell surface, the virion is supposed to be directed
to the endocytic pathway, and as response to the acidic pH of the
endosomes a conformational rearrangement occurs in E protein,
inducing fusion of the viral and cell membranes to allow viral
genome to enter the cytoplasm (Modis et al., 2003, 2004). The
inhibition here described for carrageenan when added after
adsorption of DENV-2 to the host cell suggests that the
interaction of the polysaccharide with the virion bound to the
cell surface will avoid the normal transit of the viral
nucleocapsid into the cytoplasm. The uptake of virion particles
by the cell occurs in the presence of carrageenan, as shown by
the presence of radiolabeled DENV virions and RNAmolecules,
after compound treatment during the 1 h internalization period at
37 °C (Figs. 4E–F). But, under the same experimental
conditions, the amount of internalized virus able to complete a
productive cycle in the original infected cell was reduced 2 log,
as determined by infectious center formation (Fig. 4D). In
addition, in the presence of the carrageenan the proteinase K-
resistant virus infectivity accumulated and remained inside the
cell until 150 min after adsorption similarly as occurred with
concanamycin treatment (Fig. 4G), indicating the intracellular
permanence of enveloped virions. Altogether, these results
suggest that virions enter the cell but the fusion event leading to
uncoating of the nucleocapsid and escape from the endosome is
blocked, probably due to the association of the carrageenan
with the E virion glycoprotein.
The dual sites of action of an HS-like molecule such as the λ-
carrageenan shown here on virus adsorption and uncoating
suggest that, at least in vertebrate cells, the HS residues present
in the cell membrane appear to act as attachment receptors for
DENV-2 and also, through its binding to the E protein, may
serve as mediators for virus uncoating into the host cell. At
present, many questions concerning attachment and entry of
flaviviruses are still unresolved, and particularly, the involve-
ment of HS in these processes is controversial. Several previous
studies have demonstrated attachment of DENV to HS, and,
accordingly, positively charged patches of basic residues
proposed as putative glycosaminoglycan-binding motifs were
identified within domains I, II and III of the E glycoprotein(Chen et al., 1997; Hung et al., 2004; Modis et al., 2005; Lee et
al., 2006). However, only a few studies have also provided
evidence for the requirement of HS for viral entry to
mammalian cells (Chen et al., 1997; Germi et al., 2002; Hilgard
and Stockert, 2000; Hung et al., 1999). In this study we were
able to demonstrate that an HS-imitative compound had the
ability to interfere with DENV-2 replication when added after
virus adsorption and, even, under these conditions the antiviral
potential of λ-carrageenan was higher than its ability to affect
virus adsorption (Figs. 3B, 4A and D).
Furthermore, the mode of action of carrageenans on DENV
multiplication allows to explain the differential susceptibility to
this type of compound shown by the four virus serotypes.
DENV-2 and DENV-3 were the more susceptible serotypes
whereas DENV-4 and DENV-1 exhibited a very weak inhibition
(Table 1). These results are in agreement with previous studies
about the antiviral activity of heparin and natural galactans
against DENV serotypes, reporting the high susceptibility of
DENV-2 and the lack of response by DENV-1 (Hung et al.,
1999; Talarico et al., 2005). This behavior is not surprising
given the discrepant data reported in several publications about
the cell receptors and co-receptors for DENV according to the
virus serotype and/or the host cell.
In addition to the information provided about the putative
dual function of HS for DENV-2 entry into Vero and HepG2
cells, our studies are indicative of the promising perspectives of
HS-imitative compounds such as the carrageenans as potential
antivirals to prevent virus multiplication. Given the worldwide
importance of disease caused by DENV (as described in
Introduction), several classes of inhibitors for this virus have
been reported (reviewed in Damonte et al., 2004b; Leyssen et
al., 2000). They include polyanionic substances affecting viral
binding; inhibitors of intracellular virus multiplication, blocking
nucleoside triphosphate synthesis, helicase and protease
activities; maturation inhibitors able to interfere with the post-
translational processing of E glycoprotein by cellular glucosi-
dases; nucleic acid-based antisense viral therapy; other
miscellaneous inhibitors with a presently unknown target. In
line with these objectives, the carrageenan studied here was
very effective in a treatment simultaneous with infection and
also showed strong post-exposure activity on DENV-infected
cells, proving the concept that virus entry is a valid and
interesting alternative target for anti-flavivirus therapy.
Materials and methods
Compounds and antibodies
Carrageenans type ι, λ and κ were purchased from Sigma-
Aldrich. Stock solutions of compounds were prepared in
distilled water at 2 mg/ml.
Hyperimmune sera to DENV-2 strain NGC were prepared in
rabbit by five intravenous injections at 10-day intervals of a
concentrated virus suspension containing 106 PFU in 1 ml TES
buffer (10 mM Tris–HCl pH 7.2, 100 mM NaCl, 1 mM EDTA)
and UV-irradiated during 5 min. Serum was obtained from the
central ear vein 1 week after the last injection of virus. Murine
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escence assays was gently provided by Dr. Andrea Gamarnik
(Fundación Instituto Leloir, Buenos Aires, Argentina).
Cell culture and virus infection
Vero (African green monkey kidney) cells were grown in
Eagle's minimum essential medium (MEM) (GIBCO) supple-
mented with 5% fetal bovine serum. For maintenance medium
(MM), the serum concentration was reduced to 1.5%. The C6/
36 HT mosquito cell line from A. albopictus, adapted to grow at
33 °C, was cultured in L-15 Medium (Leibovitz) supplemented
with 0.3% tryptose phosphate broth, 0.02% glutamine, 1%
MEM non-essential amino acids solution and 5% fetal bovine
serum. The human hepatoma cell line HepG2 was propagated in
MEM containing 0.03% glutamine, 0.01% sodium pyruvate and
10% fetal bovine serum.
The stocks of DENV-1 strain Hawaii, DENV-2 strain NGC,
DENV-3 strain H87 and DENV-4 strain 8124 were prepared in
C6/36 HT cells and titrated by plaque formation in Vero cells.
To obtain a concentrated stock of DENV for immune serum
preparation and RNA extraction, C6/36 HT cells were infected
with DENV-2 and supernatants were harvested at 4 and 5 days
after infection. After clarification by low-speed centrifugation,
supernatants were concentrated by pelleting for 2 h at
100,000×g. Then, the pellet was resuspended in TES buffer
by brief sonication.
To obtain radiolabeled DENV-2, C6/36 HT cells were
infected with DENV-2 and at 72 h p.i. 23 μCi/ml of
EXPRE35S-35S (NEN Dupont) was added in methionine-
cysteine-free MM. Cell supernatants were harvested at 96 h p.i.,
and radiolabeling was repeated between 96 and 120 h p.i.
Supernatants were clarified and concentrated as described
above, and the sonicated virus pellet was layered onto a 15–
60% sucrose gradient. After centrifugation at 100,000×g for
2 h, the virus band was pelleted for 2 h at 100,000×g and
resuspended by sonication.
Cytotoxicity and infectivity antiviral assays
Cell viability was measured by the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide;
Sigma-Aldrich) method. Confluent cultures in 96-well plates
were exposed to different concentrations of the carrageenans,
with three wells for each concentration, using incubation
conditions equivalent to those used in the antiviral assays. Then
10 μl of MM containing MTT (final concentration 0.5 mg/ml)
was added to each well. After 2 h of incubation at 37 °C, the
supernatant was removed and 200 μl of ethanol was added to
each well to solubilize the formazan crystals. After vigorous
shaking, absorbance was measured in a microplate reader at
595 nm. The CC50 was calculated as the compound concentra-
tion necessary to reduce cell viability by 50%.
Antiviral activity was evaluated by two methods: plaque
reduction and virus yield inhibition assays. In the plaque
reduction test, Vero cell monolayers grown in 24-well plates
were infected with about 50 PFU/well of DENV serotypes inthe absence or presence of serial two-fold concentrations of the
compounds. After adsorption, residual inoculum was replaced
by MM containing 1% methylcellulose and the corresponding
dose of each compound. Plaques were counted after 6–12 days
of incubation at 37 °C, according to virus serotype. The EC50
was calculated as the compound concentration able to reduce
virus plaques by 50%. All determinations were performed twice
and each in duplicate.
In virus yield inhibition assays, Vero and HepG2 cells were
infected with DENV-2 or DENV-3 at a multiplicity of infection
(m.o.i.) of 0.01–1 in the presence of different concentrations of
the compounds, 2 wells per concentration. After 48 h of
incubation at 37 °C, cell supernatants were collected and the
virus yields were determined by plaque formation in Vero cells.
The EC50 values were calculated as above.
Indirect immunofluorescence assay
Vero and HepG2 cells grown in coverslips were infected
with DENV-2 (m.o.i. 0.1) in the presence or absence of λ- or ι-
carrageenan (20 μg/ml). At 48 h post-infection, cell monolayers
were washed with cold PBS and fixed in methanol for 15 min at
−20 °C for cytoplasmic immunofluorescence. Indirect staining
was carried out by using anti-DENV mouse antibodies and
fluorescein (FITC)-labeled goat anti-mouse IgG. After a final
washing with PBS, cells were stained with Evans Blue and
mounted in a glycerol solution containing 1,4-diazabicyclo[2, 2,
2]octane (DABCO).
Influence of time of treatment on antiviral activity
First, a time-of-addition experiment was done by infecting
Vero and HepG2 cells with DENV-2 (m.o.i. 1) in either MM
containing 20 μg/ml of λ-carrageenan (time 0) or MM without
compound. After 1 h adsorption at 4 °C, medium containing
unadsorbed virus was removed and cell cultures were washed
with PBS. Then, MM with compound was added immediately
(time 1 h p.i.) or at 2, 3, 5 and 8 h p.i. At 10 h after infection, cell
supernatants were withdrawn, the monolayers were washed
with PBS and trypsinized with 0.25% trypsin–EDTA to dis-
perse cells. Protease treatment was stopped by adding 2 mM
phenyl-methyl-sulphonyl-fluoride (PMSF) in PBS containing
3% bovine serum albumin (PBS-BSA), then cells were washed
in PBS containing 0.2% BSA by low-speed centrifugation,
resuspended in MM and the final cell suspensions were serially
10-fold diluted and plated onto confluent monolayers of Vero
cells. After 1.5 h incubation at 37 °C, monolayers were overlaid
with MM containing 1% methylcellulose. Infectious centers
were counted after 6 days of incubation.
The influence of three different compound treatment
conditions during adsorption and/or internalization was also
determined in Vero and HepG2 cells infected with DENV-2
(m.o.i. 1). Virus adsorption: cells were exposed to DENV-2 in
the presence of 20 μg/ml of compound, and after 1 h adsorption
at 4 °C, both compound and unadsorbed virus were removed,
the cells were washed with cold PBS and overlaid with MM.
Virus internalization: cells were infected in compound-free MM
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removed, the cells were washed and further incubated at 37 °C
during 2 h in MM containing 20 μg/ml of compound.
Thereafter, cells were washed with PBS and treated with
citrate buffer (citric acid 20 mM, potassium chloride 10 mM,
sodium chloride 135 mM, pH 3) for 1 min to inactivate
adsorbed but not internalized virus. Then, cells were washed
with PBS and covered with MM. Virus adsorption and
internalization: cells were infected with DENV-2 and main-
tained in MM containing 20 μg/ml of compound during both
the 1 h adsorption period at 4 °C and the 2 h internalization
period at 37 °C. Then, cells were washed, processed with citrate
buffer as above and refed with MM. For the three treatments,
cell supernatants were harvested at 48 h after infection and
virus yields were determined by a plaque assay in Vero cells.
Virus adsorption assays
The inhibitory effect of carrageenans on virus adsorption was
measured by different experimental approaches.
(a) Infectivity assay of DENV-2 adsorption
Vero cells were infected with DENV-2 at an m.o.i. of 1 in the
presence or absence of 20 μg/ml of λ-carrageenan. After 1 h
adsorption at 4 °C, cells were washed with cold PBS to remove
unadsorbed virus and disrupted by freezing and thawing. The
amount of infectious bound virus was then measured by plaque
formation.
(b) Adsorption of DENV-2 RNA by real-time RT-PCR
Cells were infected and processed as described in (a), except
that after adsorption and extensive washing with cold PBS,
total RNA was extracted from cells by using TRIzol
(Invitrogen) according to the manufacturer's instructions. For
quantification of the amount of cell-bound viral RNA, an
iCycler IQ (Bio-Rad) employing TaqMan technology was
used. The primers and probe targeted to amplify nucleotides
10,419 to 10,493 within the viral 3′UTR were previously
described (Alvarez et al., 2005). Each 50 μl reaction mix
contained 5 μl of RNA sample and final concentrations of 1×
RT-PCR buffer (10 mM Tris–HCl pH 8.4, 50 mM KCl, 0.01%
w/v gelatin and 10 mM DTT), 2.5 mM MgCl2, 250 μM
deoxynucleoside triphosphates, 100 nM of each primer and
probe and 100 units M-MLV RT (Promega). Reverse transcrip-
tion was allowed to proceed for 1 h at 37 °C, and then 2 units of
Taq DNA polymerase (Invitrogen) were added to each reaction
tube. PCR amplification and detection were performed using
the following conditions: 95 °C for 3 min (1 cycle), and then 40
cycles of 95 °C for 15 s and 61 °C for 1 min. A standard curve
was generated using in vitro transcribed DENV replicon RNA
(Alvarez et al., 2005).
(c) Binding assay of radiolabeled DENV-2 particles
Vero cells were pretreated with PBS containing 1% calf
serum, 0.1% glucose and 0.5% BSA at 37 °C for 1 h, and
infected with 35S-radiolabeled virions in the presence or
absence of 20 μg/ml of λ-carrageenan. After 1 h adsorption at4 °C, cells were extensively washed with cold PBS, lysed in
NaOH 0.1 N–SDS 1% solution, and cell-associated radio-
activity was quantified using a liquid scintillation counter.
Virus internalization and uncoating
(a) Internalization assay of DENV-2 by infectivity
determination
Vero cells were infected with DENV-2 at an m.o.i. of 1. After
1 h adsorption at 4 °C, cells were washed with PBS and
incubated at 37 °C for 1 h in MM containing or not 20 μg/ml of
λ-carrageenan. Then, cells were washed with PBS and treated
with proteinase K (Invitrogen) for 45 min at 4 °C to remove
adsorbed but not internalized virus. After proteinase K
inactivation with 2 mM PMSF in PBS-BSA, cells were washed
with PBS containing 0.2% BSA by low-speed centrifugation,
and the pellet was resuspended in MM. Different serial dilutions
of the cell suspension were plated onto Vero cell monolayers to
quantify productive internalized virus by infectious center
formation.
(b) Internalization of DENV-2 RNA by real-time RT-PCR
Cells were infected and processed as described in (a), except
that the final cell pellet was extensively washed with PBS
containing 0.2% BSA and total RNA was extracted from cells
by using TRIzol (Invitrogen) and the amount of internalized
viral RNA was quantified by real-time RT-PCR as described
above. The number of internalized DENV RNA molecules per
culture was expressed after subtracting the amount of DENV
RNA molecules present in cultures in which immediately after
virus adsorption at 4 °C for 1 h, proteinase K treatment was
performed.
(c) Internalization assay of radiolabeled DENV-2 particles
Vero cells were pretreated with PBS containing 1% calf
serum, 0.1% glucose and 0.5% BSA at 37 °C for 1 h. Then,
radiolabeled virions were adsorbed to cells at 4 °C for 1 h, cells
were washed, incubated at 37 °C in MM with 20 μg/ml of λ-
carrageenan and processed as described in (a), except that the
final cell pellet was lysed in NaOH 0.1 N–SDS 1% solution,
and cell-associated radioactivity was quantified.
(d) Uncoating of DENV-2
DENV-2 was adsorbed to Vero cells at 4 °C for 1 h, and then
cells were washed and incubated at 37 °C with MM containing
or not either carrageenan (20 μg/ml) or concanamycin (50 nM).
At different times post-adsorption, non-internalized virus was
removed as described in (a) and the final cell pellet was
resuspended in MM, disrupted by freezing and thawing and
intracellular infectivity was determined by plaque assay.
Viral protein synthesis
Vero cells were infected with DENV-2 at an m.o.i. of 1. After
1 h at 37 °C to allow virus adsorption and internalization, cells
were washed with PBS and refed with MM in the presence or
absence of 20 μg/ml of carrageenan. At 11 h p.i., cells were
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or absence of compound for 1 h, and then labeled by addition of
100 μCi/ml of EXPRE35S-35S (NEN Dupont) for 4 h. After
labeling, cells were washed with PBS and lysed in radio-
immunoprecipitation assay (RIPA) buffer consisting of 0.15 M
NaCl, 0.1% SDS, 1% Triton X-100, 0.4 mM PMSF, 30 μl/ml
aprotinine and 1% sodium deoxycholate in 0.01 M Tris–HCl,
pH 7.4. After three cycles of freeze–thawing, samples of the
clarified cell lysates were mixed with polyclonal rabbit anti-
DENV-2 serum and incubated for 30 min at 37 °C, and 90 min
at 4 °C. Antibody–antigen complexes were collected with
protein A–sepharose, incubated for 30 min at 37 °C, and 90 min
at 4 °C, washed three times in RIPA buffer and solubilized by
boiling in sample electrophoresis buffer (5% SDS, 2% 2-
mercaptoethanol, 10% glycerol and 0.005% bromophenol blue
in 0.0625 M Tris–HCl, pH 6.8). Polypeptides were then
electrophoresed on 15% SDS-polyacrylamide slab gels and
visualized by fluorography.
RNA transfection
A DENV-2 suspension containing 106 PFU/ml was purified
and RNA was extracted from virions using the commercial kit
TOTALLY RNA (Ambion) and eluted in RNAse-free water.
RNA was quantitated by UV absorption at 260 nm. To prepare
liposomes, 5 μl of Lipofectamine 2000 (Invitrogen) was diluted
in 45 μl of Opti-MEM I medium (GIBCO). After gently
mixing, DENV-2 RNA (16 μg of RNA diluted in 50 μl of Opti-
MEM I) was added and the mixtures were incubated during
20 min. Vero cells grown in coverslips at about 90%
confluence were washed with Opti-MEM I and then incubated
with the RNA–liposome complexes for 2 h at 37 °C.
Subsequently, the supernatant containing the liposome suspen-
sion was removed, monolayers were washed with PBS and
refed with growth medium containing or not 20 μg/ml of λ-
carrageenan. After 18 h of incubation at 37 °C, supernatants
were removed, cells were washed with PBS and overlaid with
MM in the absence of compound. At 96 h post-transfection,
supernatants were harvested for plaque assay and cells were
fixed with methanol for immunofluorescence staining.
Virucidal assay
A DENV-2 suspension containing 6×105 PFU/ml was
incubated with an equal volume of MM with or without
different concentrations of carrageenan for 45 min at 37 °C. The
samples were then chilled, diluted in MM and residual
infectivity was determined by plaque formation.
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